The implantable cardiac defibrillator: Is the glass half empty or half full?

Medical Care

Volumn 45, Issue 5, 2007, Pages 371-373

  De Lissovoy, Gregory ^a,b,c  

^a UNITED BIOSOURCE CORPORATION   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COST BENEFIT ANALYSIS; DEFIBRILLATOR; ECONOMICS; EDITORIAL; HUMAN; QUALITY OF LIFE; UNITED STATES;

COST-BENEFIT ANALYSIS; DEFIBRILLATORS, IMPLANTABLE; HUMANS; QUALITY OF LIFE; UNITED STATES;

EID: 34247353351     PISSN: 00257079     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mlr.0000261741.71089.17     Document Type: Editorial

References (14)

1. Constable G, Somerville B. A Century of Innovation: Twenty Engineering Achievements That Transformed Our Lives. Washington, DC: Joseph Henry Press; 2003.
2. Health Care Financing Administration (HCFA). Program Memorandum to Fiscal Intermediaries, Transmittal No. 3 Section 35-85: Implantation of Cardiac Defibrillators; January 1986.
3. Goldberger Z, Lampert R. Implantable cardioverter-defibrillators: expanding indications and technologies. JAMA. 2006;295:809-818.
4. Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346:877-883.
5. Noyes K, Corona E, Zwanziger J, et al. Health-related quality of life consequences of implantable cardioverter defibrillators: results from MADIT II. Med Care. 2007;45:377-385.
6. Groeneveld PW, Matta MA, Suh JJ, et al. Costs and quality-of-life effects of implantable cardioverter-defibrillators. Am J Cordiol. 2006;98:1409-1415.
7. Sanders GD, Hlatky MA, Owens DK. Cost-effectiveness of implantable cardioverter-defibrillators. N Engl J Med. 2005;353:1471-1480.
8. Blue Cross Blue Shield (BCBS) Association. Special Report: Cost-Effectiveness of Implantable Cardioverter-Defibrillators in a MADIT-II Population. April 2004. Available at: http://www.bcbs.com/betterknowledge/tec/ vols/19/19_03.html. Accessed February 8, 2007.
9. Kahneman D. Determinants of health economic decisions in actual practice: the role of behavioral economics. Summary of the presentation given at the ISPOR 10th Annual International Meeting First Plenary Session, May 16, 2005, Washington: DC. Value Health. 2006;9:65-67.
10. Gehi AK, Stein RH, Metz LD, et al. Microvolt T-wave alternans for the risk stratification of ventricular tachyarrhythmic events: a meta-analysis. J Am Coll Cardiol. 2005;46:75-82.
11. Wathen MS, DeGroot PJ, Sweeney MO, et al. Prospective randomized multicenter trial of empirical antitachycardia pacing versus shocks for spontaneous rapid ventricular tachycardia in patients with implantable cardioverter-defibrillators: Pacing Fast Ventricular Tachycardia Reduces Shock Therapies (PainFREE Rx II) trial results. Circulation. 2004;110:2591-2596.
12. Schoenfeld MH, Compton SJ, Mead RH, et al. Remote monitoring of implantable cardioverter defibrillators: a prospective analysis. Pacing Clin Electrophysiol. 2004;27:757-763.
13. Matsushita K, Ishikawa T, Sumita S, et al. Daily shock impedance measured by implantable cardioverter defibrillator is useful in the management of congestive heart failure. Circ J. 2006;70:1462-1465.
14. American Heart Association. Heart Disease and Stroke Statistics - 2005 Update. Dallas, TX: American Heart Association; 2005.